GlassScriptPhysician profile
Tiffany Tsang
NPI 1164868535
$2,103.33
in general payments reported to CMS, 2019-2025
16 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.58 · 2022: $26.32 · 2023: $57.91 · 2024: $360 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $565.78 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $493.33 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $121.85 | 2024 | |
| Insulet Corporation | $107.65 | 2025 | Omnipod |
| Sequel Med Tech, LLC | $107.19 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.33 | 2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $105.76 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $104.03 | 2025 | Rezdiffra |
| Lilly USA, LLC | $102.45 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Alexion Pharmaceuticals, INC. | $84.22 | 2025 | Strensiq |
| Abbvie INC. | $74.84 | 2025 | |
| Amgen INC. | $49.99 | 2025 | Evenity |
| Recordati_rare_diseases_inc. | $32.71 | 2023-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $19.10 | 2025 | Recorlev |
| Medtronic, INC. | $14.56 | 2024 | Minimed 780g |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $13.54 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Tsang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.